Next Article in Journal
Preclinical Pharmacokinetics of C118P, a Novel Prodrug of Microtubules Inhibitor and Its Metabolite C118 in Mice, Rats, and Dogs
Previous Article in Journal
Selenate Prevents Adipogenesis through Induction of Selenoprotein S and Attenuation of Endoplasmic Reticulum Stress
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 23
Issue 11
10.3390/molecules23112881
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis of Novel Benzazole Derivatives and Evaluation of Their Antidepressant-Like Activities with Possible Underlying Mechanisms

by
Gamze Tokgöz
1,
Ümide Demir Özkay
1,*,
Derya Osmaniye
2,3,
Nazlı Turan Yücel
1,
Özgür Devrim Can
1 and
Zafer Asım Kaplancıklı
2
1
Department of Pharmacology, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey
2
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey
3
Doping and Narcotic Compounds Analysis Laboratory, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey
*
Author to whom correspondence should be addressed.
Molecules 2018, 23(11), 2881; https://doi.org/10.3390/molecules23112881
Submission received: 21 September 2018 / Revised: 31 October 2018 / Accepted: 1 November 2018 / Published: 5 November 2018
(This article belongs to the Section Medicinal Chemistry)
Browse Figures
Versions Notes

Abstract

:
Novel benzazole derivative compounds 4a–4h were obtained by the reaction of corresponding 2-(benzazol-2-ylthio)acetohydrazide and appropriate 4-substituted benzaldehydes. The chemical structures of the synthesized compounds were elucidated by FT-IR, 1H-NMR, 13C-NMR and LCMS spectroscopic methods. Antidepressant-like effects of the compounds were evaluated by tail suspension test (TST) and modified forced swimming tests (MFST). Moreover, locomotor activities of the animals were assessed by an activity cage apparatus. In the series, compounds 4a, 4b, 4e and 4f (at 50 mg/kg) significantly decreased the immobility time of mice in both of the TST and MFST. The same compounds prolonged the swimming time of animals in MFST without any change in the climbing duration. These data indicated that compounds 4a, 4b, 4e and 4f possess significant antidepressant-like activities. Moreover, pre-treatments with p-chloro-phenylalanine methyl ester (an inhibitor of serotonin synthesis), NAN-190 (a 5-HT1A antagonist), ketanserin (a 5-HT2A/2C antagonist), and ondansetron (a 5-HT3 antagonist) reversed the exhibited pharmacological effects. Results of the mechanistic studies suggested the involvement of serotonergic system and contributions of 5-HT1A, 5-HT2A/2C and 5-HT3 receptors to the antidepressant-like effects of compounds 4a, 4b, 4e and 4f. Furthermore, unchanged locomotor activity of mice following the administrations of these four derivatives confirmed that the presented antidepressant-like effects are specific.

1. Introduction

Depression is a common and incapacitating mental health condition that is estimated to affect over 300 million people worldwide. The main symptoms of depression are sad mood, loss of interest or pleasure, low self-worth, feel of guilty, lack of concentration, anhedonia, suicidal thoughts, disrupted sleep, appetite or energy [1,2]. Clinically used antidepressant drugs such as selective serotonin reuptake inhibitors, tricyclic antidepressants, and monoamine oxidase inhibitors alleviate the symptoms of major depression. However low response rates, delayed onset of therapeutic action or various side effects associated with the use of current antidepressants are still major challenges in the management of this disease limiting the success of treatment and causing compliance problems in patients [3,4]. Therefore, studies for discovering and developing new antidepressant drugs are of great importance.
The benzazole type compounds such as benzimidazoles and benzothiazoles are frequently preferred rings in drug development studies because of their widespread pharmacological activity potential. For example, various benzimidazole-based compounds have been reported for their antibacterial [5], anticancer [6], anti-HIV [7], anti-ulcer [8], anti-asthmatic [9], antidiabetic [10,11], anti-inflammatory [11], antihypertensive [12], cholinesterase inhibitory, and anti-oxidant [13] effects. Numerous benzothiazole derivatives have also been shown to induce antibacterial, antifungal, anticancer [14], anti-oxidant [15], antiviral [16], antituberculosis [17], antidiabetic [18], and anti-inflammatory [19] activities, so far.
Various compounds bearing benzimidazole or benzothiazole ring systems in their chemical structures have been demonstrated to possess potential for passing through the blood brain barrier and triggering some central nervous system (CNS)-related pharmacological activities. Actually, benzimidazole derivative compounds have been shown to induce antidepressant-like [20,21,22], antinociceptive [23,24] and anticonvulsant [10,11,25] activities. The same activities [19,26,27,28,29,30,31,32] as well as anti-Alzheimer [33,34] and neuroprotective [35] effects have also been reported for compounds carrying benzothiazole groups. Therefore, based on the CNS-related activity potential of benzimidazole and benzothiazole ring systems, in the present study, we synthesized some novel compounds carrying both of these ring systems on their chemical scaffolds and investigated their potential antidepressant-like activities using some well-known in vivo methods.

2. Results and Discussion

2.1. Chemistry

The compounds were obtained through a four-step synthesis as presented in Scheme 1. Initially, 4-substituted benzaldehyde derivatives 1a–1h were prepared by refluxing 4-fluorobenzaldehyde and appropriate secondary amines in DMF. Secondly, ethyl 2-(benzazol-2-yl-thio)acetates (2a,2b) were gained as a result of reactions between an appropriate benzazol-2-thiol and ethyl 2-chloroacetate. Thirdly, the reaction of compounds 2a,2b and excess of hydrazine hydrate afforded 2-((5-substitutedbenzazol-2-yl)thio)acetohydrazides (3a,3b), which were reacted with the appropriate 4-substituted benzaldeydes 1a–1h to afford the target compounds 4a–4h. Structure elucidations of the final compounds were performed by IR, 1H-NMR, 13C-NMR, and MS spectroscopic methods (see Supplementary Materials).

2.2. Pharmacology

In this study, antidepressant-like effects of the test compounds were investigated with tail suspension test (TST) and modified forced swimming tests (MFST), which are commonly used methods in antidepressant-like activity screening studies [36,37,38,39].
In the TST, animals are hanged from their tails. Under this short-term and inescapable stressful condition, animals become immobile following some escape-oriented movements. In this test, the duration of “immobile posture” reflecting the behavioral despair is measured. It is known that various antidepressant drugs reduce the immobility time of animals and increase the escape-related movements in the TST [40,41,42,43]. The effects of the tested compounds and reference drug fluoxetine on the immobility time of mice in the TST are illustrated in Figure 1 [F(9,60) = 10.27, p < 0.001]. Tukey HSD multiple comparison tests following one-way ANOVA demonstrated that compounds 4a, 4b, 4e, 4f and reference drug fluoxetine significantly reduced the immobility time of animals pointing out the antidepressant-like effects of these compounds.
MFST, a modified version of Porsolt’s forced swimming test, is based on the behavioral analysis of animals that are forced to swim in an inescapable narrow cylinder. Animals struggle to escape from this environment and after a while, they develop an immobile posture. This immobility behavior is considered as “behavioral despair”. Various antidepressant drugs have been reported to reduce immobility times of rodents in MFST [42,43,44]. In this study, effects of the test compounds and fluoxetine on immobility time of mice in the MFST was shown in Figure 2 [F(9,60) = 9.95, p < 0.001]. Results of the post-hoc analysis indicated that compounds 4a, 4b, 4e, 4f and fluoxetine caused significant decreases in the immobility time of mice in MFST. Findings of the MFST, revealing the antidepressant-like effects of compounds 4a, 4b, 4e and 4f, supported the data obtained from the TST.
Different from Porsolt’s forced swimming test, in MFST, durations of active movements such as swimming and climbing are taken into account in addition to the immobility behaviors of the animals. Evaluation of the active behaviors is critical, since it provides some additional clues related to the possible neurotransmitter systems playing role in the antidepressant-like effect of a test compound [45,46,47,48]. Namely, agents affecting serotonergic neurotransmission are known to reduce immobility and increase swimming times, in MFST. On the other hand, agents increasing catecholaminergic neurotransmission in the synaptic cleft have been reported to enhance climbing time while shortening the immobility durations of animals [47]. In the present study, effects of test compounds and fluoxetine on swimming and climbing time of mice in the MFST was demonstrated in Figure 3 [F(9,60) = 5.53, p < 0.001] and Figure 4 [F(9,60) = 0.82, p > 0.05], respectively. Results of the post-hoc analysis indicated that compounds 4a, 4b, 4e, 4f and fluoxetine significantly increased the swimming duration of mice while reducing the immobility time. On the other hand, none of the test compounds altered the climbing time of the animals. Therefore, it can be suggested that antidepressant-like effects of the compounds 4a, 4b, 4e and 4f might be related to the serotonergic rather than catecholaminergic mechanisms in the CNS.
It is known that agents altering motor activity performances of animals may cause “false positive” or “false negative” results, in TST and MFST [40,42,49]. For this reason, spontaneous locomotor activities of animals were also evaluated, in this study. Effects of the test compounds on horizontal and vertical locomotor activities of mice in the activity cage test were presented in Figure 5 [F(8,54) = 3.32, p < 0.01] and Figure 6 [F(8,54) = 4.52, p < 0.001], respectively. Compounds 4a, 4b, 4e and 4f, which show antidepressant-like activity in the TST and MFST, did not cause any significant changes in the horizontal and vertical spontaneous locomotor activities of the animals. These findings suggest that shortened immobility time of the animals in TST and MFST is not associated with stimulatory effects of compounds 4a, 4b, 4e and 4f. In other words, observed antidepressant-like effects are specific. On the other hand, compound 4d, which did not cause any changes in immobility or swimming time of mice, triggered a significant reduction both in the horizontal and vertical locomotor activities of animals. These decreases in the spontaneous locomotor activities may be directly related to neurosedative activity of compound 4d or possible effect of this compound on neuromuscular junction. Further studies are needed to clarify this issue.
Following the antidepressant-like activity screening studies, we conducted some further mechanistic experiments. Instead of MFST, we conducted our studies by TST, because of the lack of hypothermia risk, enhanced pharmacological sensitivity, and rapid return to normal spontaneous activity following this test [40,50].
With the aim of examining the possible involvement of the serotonergic system to the antidepressant-like effects of the compounds 4a, 4b, 4e and 4f, we used p-chlorophenylalanine methyl ester (PCPA). PCPA is an agent inhibiting tryptophan hydroxylase enzyme playing role in the synthesis of serotonin. It stops the serotonin synthesis and reduces the endogenous serotonin storage by 60–90% in the CNS of mice, when administered at 100 mg/kg daily dose for four consecutive days. PCPA does not alter central noradrenaline or dopamine levels while reducing serotonin in brain [51,52,53]. In this study, effects of PCPA pre-treatments on anti-immobility activities of the compounds 4a, 4b, 4e and 4f in the TST were exhibited in Figure 7 [F(9,60) = 11.82, p < 0.001].
Pre-treatments with PCPA reversed the compounds 4a, 4b, 4e and 4f induced shortenings in the immobility time of mice. This data indicated that antidepressant-like effects of these compounds are associated with the serotonergic neurotransmission. This result is in accordance with our experimental data obtained from the MFST tests suggesting the involvement of serotonergic system in the observed antidepressant-like effects.
After realizing the importance of serotonergic neurotransmission in the pharmacological effects of the active compounds, we tried to clarify possible serotonergic receptors participating the mechanism of action. Therefore, probable contributions of 5-HT1A, 5-HT2A/2C and 5-HT3 serotonergic receptors to the observed antidepressant-like effects were evaluated by pre-treatments with NAN-190, ketanserin and ondansetron, respectively [54,55].
The effect of NAN-190 pre-treatment on anti-immobility activities of the compounds 4a, 4b, 4e and 4f are shown in Figure 8 [F(9,60) = 18.15, p < 0.001]. NAN-190 pre-treatments reversed the anti-immobility effects of these compounds pointing out the participation of 5-HT1A receptors to the antidepressant-like effects induced by compounds 4a, 4b, 4e and 4f.
Figure 9 displays the effect of ketanserin pre-treatment on anti-immobility activities of the compounds 4a, 4b, 4e and 4f [F(9,60) = 13.66, p < 0.001].
Obtained data indicated that ketanserin pre-treatments antagonized the anti-immobility effects of these compounds pointing out the contribution of 5-HT2A/2C receptors to the exhibited antidepressant-like effects.
The effect of ondansetron pre-treatment on anti-immobility activities of the compounds 4a, 4b, 4e and 4f are shown in Figure 10 [F(9,60) = 17.36, p < 0.001]. Ondansetron pre-treatments reversed the anti-immobility effects induced by the compounds 4a, 4b, 4e and 4f suggesting the involvement of 5-HT3 receptors in the antidepressant-like effects of these compounds.
In summary, the findings acquired from the mechanistic studies indicated that compounds 4a, 4b, 4e and 4f presented significant antidepressant-like activities and 5-HT1A, 5-HT2A/2C and 5-HT3 receptors seem to contribute to these effects. These results supported the previous literature pointing out the role of serotonergic system and 5-HT1A, 5-HT2A/2C and 5-HT3 receptors [56,57,58,59] in the pharmacological mechanisms of various compounds possessing antidepressant efficacy. Actually, additional radioligand binding studies will help to confirm the involvement of these three serotonergic receptors as molecular targets of compounds 4a, 4b, 4e and 4f. On the other hand, other serotonergic receptor subtypes might also be participated to the observed pharmacological effect. Therefore, potential involvement of additional serotonergic receptors and even other neuromediator systems (GABAergic, glutaminergic, and nitrergic systems etc.) to the presented antidepressant-like activities should also be examined by further detailed studies.
Results of the in vivo studies indicated that pharmacological activities of the compounds 4a, 4b, 4e and 4f (Figure 1, Figure 2 and Figure 3) are independent of whether they contain benzimidazole (compounds 4a,4b) or benzothiazole (compounds 4e,4f) rings on the chemical scaffold. Instead, substitutions at the 4--position of the piperazine ring seem to cause the difference in the activity. More specifically, antidepressant-like effect was observed with the compounds bearing methyl and ethyl groups at the piperazine 4-position (compounds 4a,4b,4e and 4f), whereas isopropyl- and cyclopropyl-substituted compounds 4c,4d,4g and 4h were found to be ineffective. Therefore, it can be suggested that steric effects may play a role on the pharmacological activity, which is enhanced by smaller substituents such as methyl and ethyl, but abolished by relatively more bulky groups like isopropyl and cyclopropyl. On the other hand, it should be noted that increasing the number of test compounds in the series might provide a more reliable approach for the structure activity relationship related to the tested compounds.

3. Materials and Methods

3.1. Chemistry

Chemicals of the Merck (Merck KGaA, Darmstadt, Germany) or Sigma-Aldrich (Sigma-Aldrich Corp., St. Louis, MO, USA) companies were used in the synthesis. The 1H-NMR and 13C-NMR spectra were recorded in DMSO-d6 at 300 MHz and 75 MHz, pespectively, on a digital FT-NMR spectrometer (Bruker Bioscience, Billerica, MA, USA). The NMR spectra signals were defined as a singlet (s), br.s. (broad singlet), doublet (d), triplet (t), double doublet (dd), and multiplet (m). The coupling constants (J) are reported in units of Hertz (Hz). A FT-IR spectrometer (IRAffinity-1S Fourier transform, Shimadzu, Tokyo, Japan) was used to record the IR spectra of the compounds. MS studies were performed on an LCMS-8040 tandem mass system (Shimadzu) and acetonitrile containing 0.1% formic acid was used as solvent. Silica gel 60 F254 by TLC (Merck KGaA) was used to monitor the progress of reactions.

3.1.1. Synthesis of 4-Substituted Benzaldehydes 1a–1d

A solution of 4-fluorobenzaldehyde (0.017 mol, 1.82 mL) and an appropriate secondary amine in DMF (10 mL) was refluxed (0.017 mol) in the presence of potassium carbonate (K2CO3, 0.017 mol, 2.35 g). After completion of reaction, the mixture was cooled with ice-water (10 mL) and extracted with ethyl acetate (3 × 20 mL). The ethyl acetate phases were combined, and the remaining product was collected after evaporation of the solvent. The following compounds were prepared in this way: 4-(4-methylpiperazin-1-yl)benzaldehyde (1a), CAS No:27913-99-1, Yield 82%, m.p. = 55–57 °C (measured), m.p. = 58–60 °C (reported) [60]; 4-(4-ethylpiperazin-1-yl)benzaldehyde (1b), CAS No:197638-76-9, Yield 79%, obtained as an oil; 4-(4-isopropylpiperazin-1-yl)benzaldehyde (1c), CAS No:197638-78-1, Yield 84%, obtained as an oil and 4-(4-cylopropylpiperazin-1-yl)benzaldehyde (1d), CAS No:1292778-23-4, Yield 78%, obtained as an oil.

3.1.2. Synthesis of Ethyl 2-(Benzazol-2-yl-thio)acetates 2a,2b

The corresponding benzazol-2-thiol (0.015 mol), ethyl 2-chloroacetate, (0.015 mol, 1.61 mL), and K2CO3 (0.015 mol, 2.07 g) were refluxed in acetone (70 mL) for 8–10 h. After completion of the reaction, the solvent was removed using reduced pressure. The precipitated product was washed with water, dried and recrystallized from EtOH. The following compounds were preapared in this way: ethyl 2-(benzimidazole-2-ylthio)acetate (2a), CAS No:5429-62-9, Yield 65%, m.p. = 99–101 °C (measured), m.p. = 97 °C (reported) [61]; ethyl 2-(benzothiazol-2-ylthio)acetate (2b), CAS No:24044-88-0, Yield 72%, m.p. = 45–47 °C (measured), m.p. = 42–44 °C (reported) [62].

3.1.3. Synthesis of 2-((5-Substitutedbenzazol-2-yl)thio)acetohydrazides 3a,3b

A solution (20 mL) of hydrazine hydrate (5 mL) in EtOH (15 mL) was added as portions into the reaction mixture of ethyl 2-((benzazol-2-yl)thio)acetate 2a–2b (0.012 mol) in EtOH (50 mL). The reaction mixture was stirred for 5 h. The precipitated product was filtered, washed with cold-ethanol, dried and recrystallized from EtOH. To afford the following compounds: 2-((1H-benzimidazol-2-yl)thio)acetohydrazide (3a), CAS No:30065-27-1, Yield 62%, m.p. = 164–166 °C (measured), m.p. = 165–166 °C (reported) [63]; 2-((1H-benzothiazole-2-yl)thio)acetohydrazide (3b), CAS No:24044-91-5, Yield 81%, m.p. = 175–177 °C (measured), m.p. = 173–174 °C (reported) [62].

3.1.4. General Procedure for the Synthesis of the Target Compounds 4a–4h

An appropriate 2-((benzazol-2-yl)thio) acetohydrazide 3a–3b (0.002 mol), and a 4-substituted-benzaldehyde 1a–1h (0.002 mol) and a catalytic amount of acetic acid were refluxed in EtOH (30 mL) for 2 h. The mixture was cooled in an ice-bath, and the precipitated product was filtered, dried and recrystallized from EtOH.
2-((1H-Benzimidazol-2-yl)thio)-N′-(4-(4-methylpiperazin-1-yl)benzylidene)acetohydrazide (4a). Yield: 88%, FTIR (ATR, cm−1): 3572 (N-H), 2937 (C-H), 1660 (C=O), 817. 1H-NMR (DMSO-d6): δ = 2.22 (3H, s, -CH3), 2.42–2.45 (4H, m, piperazine), 3.21–3.24 (4H, m, piperazine), 3.37 (2H, s, -CH2), 6.98 (2H, d, J = 8.85 Hz, Ar-H), 7.07 (1H, t, J = 7.80 Hz, Ar-H), 7.19 (1H, t, J = 7.44 Hz, Ar-H), 7.32–7.37 (1H, m, Ar-H), 7.48–7.56 (3H, m, Ar-H), 8.07 (1H, s, Ar-H), 11.56 (1H, br.s, -NH).13C-NMR (DMSO-d6): δ = 40.82, 46.20, 47.65, 54.90, 109.68, 110.66, 115.04, 116.72, 121.49, 124.52, 128.31, 145.45, 152.24, 159.99. ESI-MS [M + H]+: 409.00 (100%).
2-((1H-Benzimidazol-2-yl)thio)-N′-(4-(4-ethylpiperazin-1-yl)benzylidene)acetohydrazide (4b). Yield: 82%, FTIR (ATR, cm−1): 3562 (N-H), 2970 (C-H), 1660 (C=O), 817. 1H-NMR (DMSO-d6): δ = 1.03 (3H, t, J = 7.17 Hz, -CH3), 2.36 (2H, q, J = 7.20 Hz, -CH2-) 2.47–2.50 (4H, m, piperazine), 3.21–3.24 (4H, m, piperazine), 3.35 (2H, s, -CH2), 6.98 (2H, d, J = 8.85 Hz, Ar-H), 7.07 (1H, t, J = 7.74 Hz, Ar-H), 7.19 (1H, t, J = 7.50 Hz, Ar-H), 7.35–7.37 (1H, m, Ar-H), 7.49–7.56 (3H, m, Ar-H), 8.07 (1H, s, Ar-H), 11.80 (1H, br.s, -NH). 13C-NMR (DMSO-d6): δ = 12.45, 40.89, 47.76, 52.08, 52.67, 109.67, 114.99, 116.71, 121.48, 124.52, 128.29, 142.94, 145.47, 148.55, 152.27, 160.00. ESI-MS [M + H]+: 423.10 (100%).
2-((1H-Benzimidazol-2-yl)thio)-N′-(4-(4-isopropylpiperazin-1-yl)benzylidene)acetohydrazide (4c). Yield: 80%, FTIR (ATR, cm−1): 3562 (N-H), 2966 (C-H), 1708 (C=O), 806. 1H-NMR (DMSO-d6): δ = 0.99 (6H, d, J = 6.45 Hz, -CH3), 2.55 (4H, br.s., piperazine), 2.62–2.69 (1H, m, -CH-), 3.21 (4H, br.s., piperazine), 4.64 (2H, s, -CH2-), 6.95 (2H, d, J = 8.85 Hz, Ar-H), 7.31–7.34 (2H, m, Ar-H), 7.53 (2H, d, J = 8.76 Hz, Ar-H), 7.63–7.66 (2H, m, Ar-H), 7.93 (1H, s, Ar-H), 11.58 (1H, s, -NH). 13C-NMR (DMSO-d6): δ = 18.67, 35.26, 48.08, 48.38, 54.12, 110.67, 114.90, 118.72, 124.04, 124.71, 125.09, 128.58, 141.73, 144.94, 148.04, 152.61, 162.74, 167.97. ESI-MS [M + H]+: 437.20 (100%).
2-((1H-Benzimidazol-2-yl)thio)-N′-(4-(4-cyclopropylpiperazin-1-yl)benzylidene)acetohydrazide (4d). Yield: 79%, FTIR (ATR, cm−1): 3550 (N-H), 2974 (C-H), 1718 (C=O), 810. 1H-NMR (DMSO-d6): δ = 0.34–0.35 (2H, m, -CH2-), 0.42-0.44 (2H, m, -CH2-), 1.62-1.65 (1H, m, -CH-), 2.65 (4H, br.s., piperazine), 3.17–3.20 (4H, m, piperazine), 4.65 (2H, s, -CH2-), 6.93–6.98 (2H, m, Ar-H), 7.07 (1H, t, J = 7.86 Hz, Ar-H), 7.19 (1H, t, J = 6.81, Ar-H) 7.31–7.33 (1H, m), 7.51–7.57 (2H, m, Ar-H), 7.63–7.65 (1H, m, Ar-H), 11.59 (1H, s, -NH). 13C-NMR (DMSO-d6): δ = 6.09, 35.27, 38.52, 47.78, 52.99, 53.04, 110.66, 115.07, 118.72, 121.46, 124.71, 125.09, 128.58, 141.73, 144.92, 148.01, 152.25, 162.76, 167.97. ESI-MS [M + H]+: 435.20 (100%).
2-(Benzothiazol-2-ylthio)-N′-(4-(4-methylpiperazin-1-yl)benzylidene)acetohydrazide (4e). Yield: 81%, FTIR (ATR, cm−1): 3313 (N-H), 2933 (C-H), 1660 (C=O), 819. 1H-NMR (DMSO-d6): δ = 2.22 (3H, s, -CH3), 2.42–2.43 (4H, m, piperazine), 3.21–3.24 (4H, m, piperazine), 4.66 (2H, s, -CH2), 6.96 (2H, t, J = 9.63 Hz, Ar-H), 7.34–7.40 (1H, m, Ar-H), 7.44–7.55 (3H, m, Ar-H), 7.85 (1H, d, J = 8.07 Hz, Ar-H), 7.93 (1H, s, Ar-H), 8.00–8.04 (1H, m, Ar-H), 11.54 (1H, s, -NH). 13C-NMR (DMSO-d6): δ = 35.61, 46.20, 47.57, 54.85, 114.98, 121.58, 122.30, 124.17, 124.92, 126.84, 128.56, 135.20, 144.74, 147.99, 152.49, 162.98, 168.29. ESI-MS [M + H]+: 426.10 (100%).
2-(Benzothiazol-2-ylthio)-N′-(4-(4-ethylpiperazin-1-yl)benzylidene)acetohydrazide (4f). Yield: 82%, FTIR (ATR, cm−1): 3228 (N-H), 2966 (C-H), 1662 (C=O), 821. 1H-NMR (DMSO-d6): δ = 1.02 (3H, t, J = 6.63 Hz, -CH3), 2.34 (2H, q, J = 7.32 Hz), 2.46 (4H, br.s., piperazine), 3.21 (4H, br.s., piperazine), 4.64 (2H, s, -CH2-), 6.94 (2H, d, J = 8.73 Hz, Ar-H), 7.35 (1H, m, Ar-H), 7.43–7.51 (3H, m, Ar-H), 7.84 (1H, d, J = 7.92 Hz, Ar-H), 7.91 (1H, s, Ar-H), 8.01 (1H, d, J = 8.67 Hz, Ar-H), 11.52 (1H, s, -NH). 13C-NMR (DMSO-d6): δ = 17.18, 40.35, 52.43, 56.82, 57.37, 119.68, 126.33, 127.05, 128.91, 129.67, 131.60, 133.31, 139.95, 149.50, 152.75, 157.27, 167.73, 173.04. ESI-MS [M + H]+: 440.11 (100%).
2-(Benzothiazol-2-ylthio)-N′-(4-(4-isopropylpiperazin-1-yl)benzylidene)acetohydrazide (4g). Yield: 82%, FTIR (ATR, cm−1): 3471 (N-H), 2960 (C-H), 1668 (C=O), 833. 1H-NMR (DMSO-d6): δ = 0.99 (6H, d, J = 6.51 Hz, -CH3), 2.50-2.51 (1H, m, -CH-), 2.54–2.57 (4H, m, piperazine), 3.19–3.22 (4H, m, piperazine), 4.66 (2H, s, -CH2-), 6.94 (2H, t, J = 9.67 Hz, Ar-H), 7.34–7.40 (1H, m, Ar-H), 7.44–7.47 (1H, m, Ar-H), 7.51 (1H, d, J = 6.30 Hz, Ar-H), 7.54 (1H, d, J = 6.12 Hz, Ar-H), 7.84–7.89 (1H, m, Ar-H), 7.93 (1H, s, Ar-H), 8.00–8.04 (1H, m, Ar-H), 11.53 (1H, s, -NH). 13C-NMR (DMSO-d6): δ = 18.66, 35.60, 48.07, 48.37, 54.13, 114.89, 121.58, 122.30, 124.09, 124.92, 126.84, 128.55, 128.85, 135.20, 144.76, 148.02, 152.57, 162.97, 168.29. ESI-MS [M + H]+: 454.13 (100%).
2-(Benzothiazol-2-ylthio)-N′-(4-(4-cyclopropylpiperazin-1-yl)benzylidene)acetohydrazide (4h). Yield: 82%, FTIR (ATR, cm−1): 3228 (N-H), 2821 (C-H), 1654 (C=O), 821. 1H-NMR (DMSO-d6): δ = 0.34–0.36 (2H, m, -CH2-), 0.41–0.44 (2H, m, -CH2-), 1.62–1.66 (1H, m, -CH-), 2.63–2.65 (4H, m, piperazine), 3.16–3.19 (4H, m, piperazine), 4.65 (2H, s, -CH2-), 6.94 (2H, t, J = 9.46 Hz, Ar-H), 7.34-7.39 (1H, m, Ar-H), 7.44–7.47 (1H, m, Ar-H), 7.50 (1H, d, J = 6.24 Hz, Ar-H), 7.53 (1H, d, J = 5.94 Hz, Ar-H), 7.85 (1H, d, J = 8.10 Hz, Ar-H), 7.92 (1H, s, Ar-H), 7.99–8.03 (1H, m, Ar-H), 11.53 (1H, s, -NH). 13C-NMR (DMSO-d6): δ = 6.08, 35.61, 47.61, 47.70, 52.99, 115.01, 121.58, 122.29, 124.16, 124.92, 126.84, 128.56, 135.20, 144.73, 147.98, 152.51, 162.97, 168.29. ESI-MS [M + H]+: 452.12 (100%).

3.2. Pharmacology

3.2.1. Animals

Adult Balb/c mice weighing 30–35 g were used for the behavioral tests. They were group-housed and maintained in standard laboratory conditions: constant temperature (24 ± 1 °C) and 12-h light/dark cycle. Animals were allowed to acclimatize to the laboratory conditions 48 h before the experiments. The experimental protocol of this study was approved by the Local Ethical Committee on Animal Experimentation of Anadolu University (Eskişehir, Turkey; date: 13.04.2018; Project no: 2018-21).

3.2.2. Experimental Groups and Treatments

Animals were randomly placed into 10 groups with seven animals in each. Efficacies of the test compounds (50 mg/kg, po) [21] were compared to control and fluoxetine (reference drug, 20 mg/kg, po) groups [37]. Vehicle, fluoxetine and test compounds were administered three times to mice at 24, 5 and 1.0 h before the experiments [37,64].

3.2.3. Evaluation of Antidepressant-Like Activity

Tail Suspension Test

TST was carried out as previously described [36,41]. In this test, mice were suspended 30 cm above the ground with an adhesive tape, which is located about one cm from tip of the tails. Animals were evaluated as immobile when they did not perform escape-oriented movements and become motionless. Total duration of the immobility behavior was measured by a chronometer over the last 4 min of the 6-min test period. Mice climbing their tails during the tests were eliminated from the tests.

Modified Forced Swimming Test

MFST was also performed to examine the antidepressant-like effects of test compounds. In this test, mice were forced to swim in a Plexiglas cylinder (30 cm height, 12 cm diameter) filled with water up to 20 cm high. The temperature of the water was set at 25 ± 1 °C. Twenty-four hours before the experiments, animals were let to swim individually in the cylinder for 15 min. In the experimental phase, mice were placed again in the cylinder and durations of immobility (the movements required to keep the head above the water), swimming (horizontal motion on the surface of the water) and climbing (upward-directed movements of the forepaws along the side of the swim chamber) behaviors over 5-s intervals were measured with a chronometer for 5 min [36,47,65].
The water in the cylinder was changed after each mouse. After pre-test and experimental phases, mice were dried carefully before returning their home cages.

3.2.4. Evaluation of Spontaneous Locomotor Activity

Activity Cage Test

Activity cage device (No. 7420, Ugo Basile, Varese, Italy) was used to assess the effects of test compounds on motor activities of mice. In this device, numbers of movements interrupting the IR beams are recorded, automatically. Horizontal and vertical spontaneous locomotor activities were recorded for 4 min. After testing each animal, the apparatus was carefully cleaned with ethanol solution [37,66].

Mechanistic Studies

Mechanistic studies were performed with PCPA (a serotonin synthesis inhibitor), NAN-190 (5-HT1A receptor antagonist), ketanserin (5-HT2A/2C receptor antagonist) and ondansetron (5-HT3 receptor antagonist) to investigate the possible involvement of the serotonergic system and serotonergic receptors in the antidepressant-like effects of test compounds. PCPA was intraperitoneally administered at dose of 100 mg/kg for four consecutive days. Test compounds were applied 24 h after the last injection and 1 h later, animals were subjected to the TST [54]. NAN-190 (0.5 mg/kg i.p.), ketanserin (1 mg/kg i.p.), ondansetron (0.3 mg/kg i.p.) were injected 15 min prior to the administration of the test compounds. Then, TST was conducted 1 h later [36].

Statistical Analysis

Graphpad Prism ver. 6.01 (GraphPad Software, San Diego, CA, USA) was used for statistical analyses and for the preparation of graphical presentations. Obtained data was analyzed using one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons test. Results were expressed as the mean ± standard error of the mean (SEM). Differences between the groups were considered as statistically significant if p < 0.05.

4. Conclusions

Data obtained from this study presented that test compounds 4a, 4b, 4e and 4f possess significant antidepressant-like efficacy mediated through serotonergic system and 5-HT1A, 5-HT2A/2C 5-HT3 serotonergic receptors. These results supported to the previous literature findings pointing out the antidepressant capacity of benzazole derivative compounds [20,21,22,26,27]. On the other hand, to clarify the exact mechanism of action possible contribution of other neurotransmitter systems (such as opioidergic, GABAergic, glutaminergic, and nitrergic systems) should also be investigated by further studies.

Supplementary Materials

The 13C-NMR, 1H-NMR, FTIR, and MS spectrums of compounds 4a–4h are available online.

Author Contributions

Conceptualization and design of the study, Ü.D.Ö. and Z.A.K.; Synthesis of the compounds: Z.A.K. and D.O., Conducting pharmacological tests G.T. and N.T.Y.; Statistical analysis of the data Ü.D.Ö. and Ö.D.C.; Writing of the manuscript Ü.D.Ö. and Ö.D.C.; Proofreading Z.A.K.

Acknowledgments

This research was supported from the Anadolu University Scientific Research Projects Commission (Project No: 1805S189).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. WHO, mhGAP Intervention Guide for Mental, Neurological and Substance Use Disorders in Non-Specialized Health Settings. 2010. Available online: http://apps.who.int/iris/bitstream/10665/44406/1/9789241548069_eng.pdf (accessed on 1 May 2018).
  2. WHO, DEPRESSION: A Global Crisis World Mental Health Day. 2012. Available online: http://www.who.int/mental_health/management/depression/wfmh_paper_depression_wmhd_2012.pdf (accessed on 1 May 2018).
  3. Paschos, K.A.; Veletza, S.; Chatzaki, E. Neuropeptide and sigma receptors as novel therapeutic targets for the pharmacotherapy of depression. CNS Drugs 2009, 23, 755–772. [Google Scholar] [CrossRef] [PubMed]
  4. Yue, N.; Li, B.; Yang, L.; Han, Q.Q.; Huang, H.J.; Wang, Y.L.; Wang, J.; Yu, R.; Wu, G.C.; Liu, Q.; et al. Electro-Acupuncture Alleviates Chronic Unpredictable Stress-Induced Depressive- and Anxiety-Like Behavior and Hippocampal Neuroinflammation in Rat Model of Depression. Front. Mol. Neurosci. 2018. [Google Scholar] [CrossRef] [PubMed]
  5. Ajani, O.O.; Tolu-Bolaji, O.O.; Olorunshola, S.J.; Zhao, Y.; Aderohunmu, D.V. Structure-based design of functionalized 2-substituted and 1,2-disubstituted benzimidazole derivatives and their in vitro antibacterial efficacy. J. Adv. Res. 2017, 8, 703–712. [Google Scholar] [CrossRef] [PubMed]
  6. Ibrahim, H.A.; Awadallah, F.M.; Refaat, H.M.; Amin, K.M. Molecular docking simulation, synthesis and 3D pharmacophore studies of novel 2-substituted-5-nitro-benzimidazole derivatives as anticancer agents targeting VEGFR-2 and c-Met. Bioorg. Chem. 2018, 77, 457–470. [Google Scholar] [CrossRef] [PubMed]
  7. Singh, A.; Yadav, D.; Yadav, M.; Dhamanage, A.; Kulkarni, S.; Singh, R.K. Molecular modeling, synthesis and biological evaluation of N-heteroaryl compounds as reverse transcriptase inhibitors against HIV-1. Chem. Biol. Drug Des. 2015, 85, 336–347. [Google Scholar] [CrossRef] [PubMed]
  8. Noor, A.; Qazi, N.G.; Nadeem, H.; Khan, A.U.; Paracha, R.Z.; Ali, F.; Saeed, A. Synthesis, characterization, anti-ulcer action and molecular docking evaluation of novel benzimidazole-pyrazole hybrids. Chem. Cent. J. 2017, 11, 85. [Google Scholar] [CrossRef] [PubMed]
  9. Vaidya, S.D.; Kumar, B.V.S.; Kumar, R.V.; Bhise, U.N.; Mashelkar, U.C. Synthesis, anti-bacterial, anti-asthmatic and anti-diabetic activities of novel N-substituted-2-(benzo[d]isoxazol-3-ylmethyl)-1H-benzimidazoles. J. Heterocycl. Chem. 2007, 44, 685–691. [Google Scholar] [CrossRef]
  10. Shingalapur, R.V.; Hosamani, K.M.; Keri, R.S.; Hugar, M.H. Derivatives of benzimidazole pharmacophore: Synthesis, anticonvulsant, antidiabetic and DNA cleavage studies. Eur. J. Med. Chem. 2010, 45, 1753–1759. [Google Scholar] [CrossRef] [PubMed]
  11. Shaikh, I.N.; Hosamani, K.M.; Seetharamareddy, H.R.; Hugar, M.H. Synthesis and in-vivo evaluation of carbonyl-amide linkage based new benzimidazole derivatives. Arch. Pharm. 2012, 345, 65–72. [Google Scholar] [CrossRef] [PubMed]
  12. Zhu, W.; Da, Y.; Wu, D.; Zheng, H.; Zhu, L.; Wang, L.; Yan, Y.; Chen, Z. Design, synthesis and biological evaluation of new 5-nitro benzimidazole derivatives as AT1 antagonists with anti-hypertension activities. Bioorg. Med. Chem. 2014, 22, 2294–2302. [Google Scholar] [CrossRef] [PubMed]
  13. Alpan, A.S.; Sarıkaya, G.; Çoban, G.; Parlar, S.; Armagan, G.; Alptüzün, V. Mannich-Benzimidazole Derivatives as Antioxidant and Anticholinesterase Inhibitors: Synthesis, Biological Evaluations, and Molecular Docking Study. Arch. Pharm. 2017. [Google Scholar] [CrossRef] [PubMed]
  14. Lad, N.P.; Manohar, Y.; Mascarenhas, M.; Pandit, Y.B.; Kulkarni, M.R.; Sharma, R.; Salkar, K.; Suthar, A.; Pandit, S.S. Methylsulfonyl benzothiazoles (MSBT) derivatives: Search for new potential antimicrobial and anticancer agents. Bioorg. Med. Chem. Lett. 2017, 27, 1319–1324. [Google Scholar] [CrossRef] [PubMed]
  15. Karali, N.; Güzel, O.; Ozsoy, N.; Ozbey, S.; Salman, A. Synthesis of new spiroindolinones incorporating a benzothiazole moiety as antioxidant agents. Eur. J. Med. Chem. 2010, 45, 1068–1077. [Google Scholar] [CrossRef] [PubMed]
  16. Akhtar, M.J.; Khan, A.A.; Ali, Z.; Dewangan, R.P.; Rafi, M.; Hassan, M.Q.; Akhtar, M.S.; Siddiqui, A.A.; Partap, S.; Pasha, S.; et al. Synthesis of stable benzimidazole derivatives bearing pyrazole as anticancer and EGFR receptor inhibitors. Bioorg. Chem. 2018, 78, 158–169. [Google Scholar] [CrossRef] [PubMed]
  17. Netalkar, P.P.; Netalkar, S.P.; Budagumpi, S.; Revankar, V.K. Synthesis, crystal structures and characterization of late first row transition metal complexes derived from benzothiazole core: Anti-tuberculosis activity and special emphasis on DNA binding and cleavage property. Eur. J. Med. Chem. 2014, 79, 47–56. [Google Scholar] [CrossRef] [PubMed]
  18. Meltzer-Mats, E.; Babai-Shani, G.; Pasternak, L.; Uritsky, N.; Getter, T.; Viskind, O.; Eckel, J.; Cerasi, E.; Senderowitz, H.; Sasson, S.; et al. Synthesis and mechanism of hypoglycemic activity of benzothiazole derivatives. J. Med. Chem. 2013, 56, 5335–5350. [Google Scholar] [CrossRef] [PubMed]
  19. Azam, M.A.; Dharanya, L.; Mehta, C.C.; Sachdeva, S. Synthesis and biological evaluation of some novel pyrazolopyrimidines incorporating a benzothiazole ring system. Acta Pharm. 2013, 63, 19–30. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  20. Mute, V.M.; Bodhankar, S.L. Antidepressant like effect of newly synthesized compound 2[(N-benzylacetamido) mercapto] benzimidazole (vs 25) and its possible mechanism by inhibition of monoamine oxidase enzyme in mice. Int. J. Pharm. Pharm. Sci. 2015, 7, 407–410. [Google Scholar]
  21. Khan, I.; Tantray, M.A.; Hamid, H.; Alam, M.S.; Kalam, A.; Dhulap, A. Synthesis of benzimidazole based thiadiazole and carbohydrazide conjugates as glycogen synthase kinase-3β inhibitors with anti-depressant activity. Bioorg. Med. Chem. Lett. 2016, 26, 4020–4024. [Google Scholar] [CrossRef] [PubMed]
  22. Tantray, M.A.; Khan, I.; Hamid, H.; Alam, M.S.; Dhulap, A.; Kalam, A. Synthesis of benzimidazole-based 1,3,4-oxadiazole-1,2,3-triazole conjugates as glycogen synthase kinase-3b inhibitors with antidepressant activity in in vivo models. SC Adv. 2016, 6, 43345–43355. [Google Scholar]
  23. Kamil, A.; Akhtar, S.; Khan, A.; Farooq, E.; Nishan, U.; Uddin, R.; Farooq, U. Synthesis, structure–activity relationship and antinociceptive activities of some 2-(2′-pyridyl) benzimidazole derivatives. Med. Chem. Res. 2016, 25, 1216–1228. [Google Scholar] [CrossRef]
  24. Palin, R.; Clark, J.K.; Evans, L.; Houghton, A.K.; Jones, P.S.; Prosser, A.; Wishart, G.; Yoshiizumi, K. Structure-activity relationships and CoMFA of N-3 substituted phenoxypropyl piperidine benzimidazol-2-one analogues as NOP receptor agonists with analgesic properties. Bioorg. Med. Chem. 2008, 16, 2829–2851. [Google Scholar] [CrossRef] [PubMed]
  25. Jain, P.; Sharma, P.K.; Rajak, H.; Pawar, R.S.; Patil, U.K.; Singour, P.K. Design, synthesis and biological evaluation of some novel benzimidazole derivatives for their potential anticonvulsant activity. Arch. Pharm. Res. 2010, 33, 971–980. [Google Scholar] [CrossRef] [PubMed]
  26. Siddiqui, N.; Rana, A.; Khan, S.A.; Ahsan, W.; Alam, M.S.; Ahmed, S. Analgesic and antidepressant activities of benzothiazole-benzamides. Biomed. Pharmacol. J. 2008, 1, 297–300. [Google Scholar]
  27. Wang, S.; Chen, Y.; Zhao, S.; Xu, X.; Liu, X.; Liu, B.F.; Zhang, G. Synthesis and biological evaluation of a series of benzoxazole/benzothiazole-containing 2,3-dihydrobenzo[b][1,4]dioxine derivatives as potential antidepressants. Bioorg. Med. Chem. Lett. 2014, 24, 1766–1770. [Google Scholar] [CrossRef] [PubMed]
  28. Ali, R.; Siddiqui, N. New benzo[d]thiazol-2-yl-aminoacetamides as potential anticonvulsants: Synthesis, activity and prediction of molecular properties. Arch. Pharm. 2015, 348, 254–265. [Google Scholar] [CrossRef] [PubMed]
  29. Liu, D.C.; Zhang, H.J.; Jin, C.M.; Quan, Z.S. Synthesis and biological evaluation of novel benzothiazole derivatives as potential anticonvulsant agents. Molecules 2016, 21, 164. [Google Scholar] [CrossRef] [PubMed]
  30. Kaplancikli, Z.A.; Altintop, M.D.; Turan-Zitouni, G.; Ozdemir, A.; Can, O.D. Synthesis and analgesic activity of some acetamide derivatives. J. Enzyme Inhib. Med. Chem. 2012, 27, 275–280. [Google Scholar] [CrossRef] [PubMed]
  31. Hamdy, N.A.; Abdel-Aziz, H.A.; Kamel, G.M.; Fakhr, I.M. Convenient synthesis, anti-inflammatory, analgesic and ulcerogenic activites of some new bis-hydrazones and pyrazole derivatives. Acta Pol. Pharm. 2013, 70, 469–480. [Google Scholar] [PubMed]
  32. Gökce, M.I.; Cakir, B.; Erol, K.; Sahin, M.F. Synthesis and antinociceptive activity of [(2-oxobenzothiazolin-3-yl)methyl]-4-alkyl/aryl-1,2,4-triazoline-5-thiones. Arch. Pharm. 2001, 334, 279–283. [Google Scholar] [CrossRef]
  33. Ozkay, U.D.; Can, O.D.; Özkay, Y.; Öztürk, Y. Effect of benzothiazole/piperazine derivatives on intracerebroventricular streptozotocin-induced cognitive deficits. Pharmacol. Rep. 2012, 64, 834–847. [Google Scholar] [CrossRef]
  34. Keri, R.S.; Quintanova, C.; Marques, S.M.; Esteves, A.R.; Cardoso, S.M.; Santos, M.A. Design, synthesis and neuroprotective evaluation of novel tacrine-benzothiazole hybrids as multi-targeted compounds against Alzheimer’s disease. Bioorg. Med. Chem. 2013, 21, 4559–4569. [Google Scholar] [CrossRef] [PubMed]
  35. Carboni, S.; Hiver, A.; Szyndralewiez, C.; Gaillard, P.; Gotteland, J.P.; Vitte, P.A. AS601245 (1,3-benzothiazol-2 -yl(2-[[2-(3-pyridinyl)ethyl]amino]-4-pyrimidinyl)acetonitrile): A c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties. J. Pharmacol. Exp. Ther. 2004, 310, 25–32. [Google Scholar] [CrossRef] [PubMed]
  36. Can, Ö.D.; Turan, N.; Demir Özkay, Ü.; Öztürk, Y. Antidepressant-like effect of gallic acid in mice: Dual involvement of serotonergic and catecholaminergic systems. Life Sci. 2017, 190, 110–117. [Google Scholar] [CrossRef] [PubMed]
  37. Demir Özkay, Ü.; Yurttas, L.; Özkay, Y.; Üçel, U.I.; Can, Ö.D.; Öztürk, Y. Synthesis of new 1-phenyl-2-(4-substituted-piperazin-1-yl)-propanol derivatives and evaluation of their antidepressant-like effects. Arch. Pharm. Res. 2013, 36, 802–811. [Google Scholar] [CrossRef] [PubMed]
  38. Can, A.; Dao, D.T.; Terrillion, C.E.; Piantadosi, S.C.; Bhat, S.; Gould, T.D. The tail suspension test. J. Vis. Exp. 2012. [Google Scholar] [CrossRef] [PubMed]
  39. Slattery, D.A.; Cryan, J.F. Using the rat forced swim test to assess antidepressant-like activity in rodents. Nat. Protoc. 2012, 7, 1009–1014. [Google Scholar] [CrossRef] [PubMed]
  40. Cryan, J.F.; Mombereau, C.; Vassout, A. The tail suspension test for assessing antidepressant activity: Review of pharmacological and genetic studies in mice. Neurosci. Biobehav. Rev. 2005, 29, 571–625. [Google Scholar] [CrossRef] [PubMed]
  41. Steru, L.; Chermat, R.; Thierry, B.; Simon, P. The tail suspension test: A new method for screening antidepressants in mice. Psychopharmacology 1985, 85, 367–370. [Google Scholar] [CrossRef] [PubMed]
  42. Brocardo, P.S.; Budni, J.; Kaster, M.P.; Santos, A.R.; Rodrigues, A.L. Folic acid administration produces an antidepressant-like effect in mice: Evidence for the involvement of the serotonergic and noradrenergic systems. Neuropharmacology 2008, 54, 464–473. [Google Scholar] [CrossRef] [PubMed]
  43. Girish, C.; Raj, V.; Arya, J. Balakrishnan, S. Evidence for the involvement of the monoaminergic system, but not the opioid system in the antidepressant-like activity of ellagic acid in mice. Eur. J. Pharmacol. 2012, 682, 118–125. [Google Scholar] [CrossRef] [PubMed]
  44. Porsolt, R.D.; Bertin, A.; Jalfre, M. Behavioral despair in mice: A primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 1977, 229, 327–336. [Google Scholar] [PubMed]
  45. Detke, M.J.; Lucki, I. Detection of serotonergic and noradrenergic antidepressants in the rat forced swimming test: The effects of water depth. Behav. Brain Res. 1996, 73, 43–46. [Google Scholar] [CrossRef]
  46. Aksoz, E.; Aksoz, T.; Bilge, S.S.; Ilkaya, F.; Celik, S.; Diren, H.B. Antidepressant-like effects of echo-planar magnetic resonance imaging in mice determined using the forced swimming test. Brain Res. 2008, 1236, 194–199. [Google Scholar] [CrossRef] [PubMed]
  47. Cryan, J.F.; Markou, A.; Lucki, I. Assessing antidepressant activity in rodents: Recent developments and future needs. Trends Pharmacol. Sci. 2002, 23, 238–245. [Google Scholar] [CrossRef]
  48. Nakatomi, Y.; Yokoyama, C.; Kinoshita, S.; Masaki, D.; Tsuchida, H.; Onoe, H.; Yoshimoto, K.; Fukui, K. Serotonergic mediation of the antidepressant-like effect of the green leaves odor in mice. Neurosci. Lett. 2008, 436, 167–170. [Google Scholar] [CrossRef] [PubMed]
  49. Abreu, T.M.; Monteiro, V.S.; Martins, A.B.S.; Teles, F.B.; da Conceição Rivanor, R.L.; Mota, É.F.; Macedo, D.S.; De Vasconcelos, S.M.M.; Júnior, J.E.R.H.; Benevides, N.M.B. Involvement of the dopaminergic system in the antidepressant-like effect of the lectin isolated from the red marine alga Solieria filiformis in mice. Int. J. Biol. Macromol. 2018, 111, 534–541. [Google Scholar] [CrossRef] [PubMed]
  50. Castagné, V.; Moser, P.; Roux, S.; Porsolt, R.D. Rodent models of depression: Forced swim and tail suspension behavioral despair tests in rats and mice. Curr. Protoc. Neurosci. 2011. [Google Scholar] [CrossRef]
  51. Koe, B.K.; Weissman, A. p-Chlorophenylalanine: A specific depletor of brain serotonin. J. Pharmacol. Exp. Ther. 1966, 154, 499–516. [Google Scholar] [PubMed]
  52. Redrobe, J.P.; Bourin, M.; Colombel, M.C.; Baker, G.B. Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology 1998, 138, 1–8. [Google Scholar] [CrossRef] [PubMed]
  53. Redrobe, J.P.; Bourin, M.; Colombel, M.C.; Baker, G.B. Psychopharmacological profile of the selective serotonin reuptake inhibitor, paroxetine: Implication of noradrenergic and serotonergic mechanisms. J. Psychopharmacol. 1998, 12, 348–355. [Google Scholar] [CrossRef] [PubMed]
  54. Kwon, S.; Lee, B.; Kim, M.; Lee, H.; Park, H.J.; Hahm, D.H. Antidepressant-like effect of the methanolic extract from Bupleurum falcatum in the tail suspension test. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2010, 34, 265–270. [Google Scholar] [CrossRef] [PubMed]
  55. Can, Ö.D.; Demir Özkay, Ü.; Üçel, U.İ. Anti-depressant-like effect of vitexin in BALB/c mice and evidence for the involvement of monoaminergic mechanisms. Eur J. Pharmacol. 2013, 699, 250–257. [Google Scholar] [CrossRef] [PubMed]
  56. Lian, L.; Xu, Y.; Zhang, J.; Yu, Y.; Zhu, N.; Guan, X.; Huang, H.; Chen, R.; Chen, J.; Shi, G.; et al. Antidepressant-like effects of a novel curcumin derivative J147: Involvement of 5-HT1A receptor. Neuropharmacology 2018, 135, 506–513. [Google Scholar] [CrossRef] [PubMed]
  57. Wang, R.; Xu, Y.; Wu, H.L.; Li, Y.B.; Li, Y.H.; Guo, J.B.; Li, X.J. The antidepressant effects of curcumin in the forced swimming test involve 5-HT1 and 5-HT2 receptors. Eur. J. Pharmacol. 2008, 578, 43–50. [Google Scholar] [CrossRef] [PubMed]
  58. Karim, N.; Khan, I.; Abdelhalim, A.; Khan, A.; Halim, S.A. Antidepressant potential of novel flavonoids derivatives from sweet violet (Viola odorata L): Pharmacological, biochemical and computational evidences for possible involvement of serotonergic mechanism. Fitoterapia 2018, 128, 148–161. [Google Scholar] [CrossRef] [PubMed]
  59. Wang, G.L.; Wang, Y.P.; Zheng, J.Y.; Zhang, L.X. Monoaminergic and aminoacidergic receptors are involved in the antidepressant-like effect of ginsenoside Rb1 in mouse hippocampus (CA3) and prefrontal cortex. Brain Res. 2018, 1699, 44–53. [Google Scholar] [CrossRef] [PubMed]
  60. Chen, L.; Jin, Y.; Fu, W.; Xiao, S.; Feng, C.; Fang, B.; Gu, Y.; Li, C.; Zhao, Y.; Liu, Z.; et al. Design, Synthesis, and Structure-Activity Relationship Analysis of Thiazolo [3,2-a]pyrimidine Derivatives with Anti-inflammatory Activity in Acute Lung Injury. Chem. Med. Chem. 2017, 12, 1022–1032. [Google Scholar] [CrossRef] [PubMed]
  61. Faraji, L.; Shahkarami, S.; Nadri, H.; Moradi, A.; Saeedi, M.; Foroumadi, A.; Ramazani, A.; Haririan, I.; Ganjali, M.R.; Shafiee, A.; et al. Synthesis of novel benzimidazole and benzothiazole derivatives bearing a 1,2,3-triazole ring system and their acetylcholinesterase inhibitory activity. J. Chem. Res. 2017, 41, 1–63. [Google Scholar] [CrossRef]
  62. Al Omran, F.; Abou El-Khair, A. Synthesis, spectroscopy and X-ray characterization of novel derivatives of substituted 2-(benzothiazol-2′-ylthio)acetohydrazide. IJOC 2016, 6, 31–43. [Google Scholar] [CrossRef]
  63. Bhatt, J.D.; Nimavat, K.S.; Vyas, K.B. Studies on novel thiazolidinone and their biological studies. J. Chem. Pharm. Res. 2013, 5, 327–331. [Google Scholar]
  64. Sanmukhani, J.; Anovadiya, A.; Tripathi, C.B. Evaluation of antidepressant like activity of curcumin and its combination with fluoxetine and imipramine: An acute and chronic study. Acta Pol. Pharm. 2011, 68, 769–775. [Google Scholar] [PubMed]
  65. Tanaka, M.; Telegdy, G. Involvement of adrenergic and serotonergic receptors in antidepressant-like effect of urocortin 3 in a modified forced swimming test in mice. Brain Res. Bull. 2008, 77, 301–305. [Google Scholar] [CrossRef] [PubMed]
  66. Votava, M.; Hess, L.; Slíva, J.; Krsiak, M.; Agová, V. Dexmedetomidine selectively suppresses dominant behaviour in aggressive and sociable mice. Eur. J. Pharmacol. 2005, 523, 79–85. [Google Scholar] [CrossRef] [PubMed]
Sample Availability: Samples of the compounds are available from the authors.
Molecules 23 02881 sch001 550
Scheme 1. Synthesis of the target compounds 4a–4h.
Scheme 1. Synthesis of the target compounds 4a–4h.
Molecules 23 02881 sch001

Comp.XR
4a-NHMethyl
4b-NHEthyl
4c-NHIsopropyl
4d-NHCyclopropyl
4e-SMethyl
4f-SEthyl
4g-SIsopropyl
4h-SCyclopropyl
Molecules 23 02881 g001 550
Figure 1. The effect of 4a–4h (50 mg/kg) and fluoxetine (20 mg/kg) on immobility time of animals in the tail suspension test. ** p < 0.01, *** p < 0.001, compared with control group; One way analysis of variance followed by Tukey HSD multiple comparison test, n = 7.
Figure 1. The effect of 4a–4h (50 mg/kg) and fluoxetine (20 mg/kg) on immobility time of animals in the tail suspension test. ** p < 0.01, *** p < 0.001, compared with control group; One way analysis of variance followed by Tukey HSD multiple comparison test, n = 7.
Molecules 23 02881 g001
Molecules 23 02881 g002 550
Figure 2. The effect of 4a–4h (50 mg/kg) and fluoxetine (20 mg/kg) on immobility time of animals in the modified forced swimming test. * p < 0.05, ** p < 0.01, *** p < 0.001, compared with control group; One way analysis of variance followed by Tukey HSD multiple comparison test, n = 7.
Figure 2. The effect of 4a–4h (50 mg/kg) and fluoxetine (20 mg/kg) on immobility time of animals in the modified forced swimming test. * p < 0.05, ** p < 0.01, *** p < 0.001, compared with control group; One way analysis of variance followed by Tukey HSD multiple comparison test, n = 7.
Molecules 23 02881 g002
Molecules 23 02881 g003 550
Figure 3. The effect of 4a–4h (50 mg/kg) and fluoxetine (20 mg/kg) on swimming time of animals in the modified forced swimming test. * p < 0.05, ** p < 0.01, *** p < 0.001, compared with control group; One way analysis of variance followed by Tukey HSD multiple comparison test, n = 7.
Figure 3. The effect of 4a–4h (50 mg/kg) and fluoxetine (20 mg/kg) on swimming time of animals in the modified forced swimming test. * p < 0.05, ** p < 0.01, *** p < 0.001, compared with control group; One way analysis of variance followed by Tukey HSD multiple comparison test, n = 7.
Molecules 23 02881 g003
Molecules 23 02881 g004 550
Figure 4. The effect of 4a–4h (50 mg/kg) and fluoxetine (20 mg/kg) on climbing time of animals in the modified forced swimming test. One way analysis of variance followed by Tukey HSD multiple comparison test, n = 7.
Figure 4. The effect of 4a–4h (50 mg/kg) and fluoxetine (20 mg/kg) on climbing time of animals in the modified forced swimming test. One way analysis of variance followed by Tukey HSD multiple comparison test, n = 7.
Molecules 23 02881 g004
Molecules 23 02881 g005 550
Figure 5. The effect of 4a–4h (50 mg/kg) on horizontal locomotor activities of animals in the activity cage test. ** p < 0.01, compared with control group; One way analysis of variance followed by Tukey HSD multiple comparison test, n = 7.
Figure 5. The effect of 4a–4h (50 mg/kg) on horizontal locomotor activities of animals in the activity cage test. ** p < 0.01, compared with control group; One way analysis of variance followed by Tukey HSD multiple comparison test, n = 7.
Molecules 23 02881 g005
Molecules 23 02881 g006 550
Figure 6. The effect of 4a–4h (50 mg/kg) on vertical locomotor activities of animals in the activity cage test. * p < 0.05, compared with control group; One way analysis of variance followed by Tukey HSD multiple comparison test, n = 7.
Figure 6. The effect of 4a–4h (50 mg/kg) on vertical locomotor activities of animals in the activity cage test. * p < 0.05, compared with control group; One way analysis of variance followed by Tukey HSD multiple comparison test, n = 7.
Molecules 23 02881 g006
Molecules 23 02881 g007 550
Figure 7. Effect of PCPA (100 mg/kg) pre-treatments on antidepressant-like activity induced by compounds 4a, 4b, 4e and 4f in the tail suspension test. ** p < 0.01, *** p < 0.001, compared with control group; b p < 0.01, compared with compound 4a administrated group; & p < 0.05, compared with compound 4b administrated group; + p < 0.05, compared with compound 4e administrated group; éé p < 0.01, compared with compound 4f administrated group; One way analysis of variance followed by Tukey HSD multiple comparison test, n = 7.
Figure 7. Effect of PCPA (100 mg/kg) pre-treatments on antidepressant-like activity induced by compounds 4a, 4b, 4e and 4f in the tail suspension test. ** p < 0.01, *** p < 0.001, compared with control group; b p < 0.01, compared with compound 4a administrated group; & p < 0.05, compared with compound 4b administrated group; + p < 0.05, compared with compound 4e administrated group; éé p < 0.01, compared with compound 4f administrated group; One way analysis of variance followed by Tukey HSD multiple comparison test, n = 7.
Molecules 23 02881 g007
Molecules 23 02881 g008 550
Figure 8. Effect of NAN-190 (0.5 mg/kg) pre-treatments on antidepressant-like activity induced by compounds 4a, 4b, 4e and 4f in the tail suspension test. ** p < 0.01, *** p < 0.001, compared with control group; b p < 0.01, compared with compound 4a administrated group; &&& p < 0.001, compared with compound 4b administrated group; +++ p < 0.001, compared with compound 4e administrated group; ééé p < 0.001, compared with compound 4f administrated group; One way analysis of variance followed by Tukey HSD multiple comparison test, n = 7.
Figure 8. Effect of NAN-190 (0.5 mg/kg) pre-treatments on antidepressant-like activity induced by compounds 4a, 4b, 4e and 4f in the tail suspension test. ** p < 0.01, *** p < 0.001, compared with control group; b p < 0.01, compared with compound 4a administrated group; &&& p < 0.001, compared with compound 4b administrated group; +++ p < 0.001, compared with compound 4e administrated group; ééé p < 0.001, compared with compound 4f administrated group; One way analysis of variance followed by Tukey HSD multiple comparison test, n = 7.
Molecules 23 02881 g008
Molecules 23 02881 g009 550
Figure 9. Effect of ketanserin (1 mg/kg) pre-treatments on antidepressant-like activity induced by compounds 4a, 4b, 4e and 4f in the tail suspension test. ** p < 0.01, *** p < 0.001, compared with control group; b p < 0.01, compared with compound 4a administrated group; &&& p < 0.001, compared with compound 4b administrated group; +++ p < 0.001, compared with compound 4e administrated group; éé p < 0.01, compared with compound 4f administrated group; One way analysis of variance followed by Tukey HSD multiple comparison test, n = 7.
Figure 9. Effect of ketanserin (1 mg/kg) pre-treatments on antidepressant-like activity induced by compounds 4a, 4b, 4e and 4f in the tail suspension test. ** p < 0.01, *** p < 0.001, compared with control group; b p < 0.01, compared with compound 4a administrated group; &&& p < 0.001, compared with compound 4b administrated group; +++ p < 0.001, compared with compound 4e administrated group; éé p < 0.01, compared with compound 4f administrated group; One way analysis of variance followed by Tukey HSD multiple comparison test, n = 7.
Molecules 23 02881 g009
Molecules 23 02881 g010 550
Figure 10. Effect of ondansetron (0.3 mg/kg) pre-treatments on antidepressant-like activity induced by compounds 4a, 4b, 4e and 4f in the tail suspension test. *** p < 0.001, compared with control group; a p < 0.05, compared with compound 4a administrated group; & p < 0.05, compared with compound 4b administrated group; +++ p < 0.001, compared with compound 4e administrated group; ééé p < 0.001, compared with compound 4f administrated group; One way analysis of variance followed by Tukey HSD multiple comparison test, n = 7.
Figure 10. Effect of ondansetron (0.3 mg/kg) pre-treatments on antidepressant-like activity induced by compounds 4a, 4b, 4e and 4f in the tail suspension test. *** p < 0.001, compared with control group; a p < 0.05, compared with compound 4a administrated group; & p < 0.05, compared with compound 4b administrated group; +++ p < 0.001, compared with compound 4e administrated group; ééé p < 0.001, compared with compound 4f administrated group; One way analysis of variance followed by Tukey HSD multiple comparison test, n = 7.
Molecules 23 02881 g010

Share and Cite

MDPI and ACS Style

Tokgöz, G.; Demir Özkay, Ü.; Osmaniye, D.; Turan Yücel, N.; Can, Ö.D.; Kaplancıklı, Z.A. Synthesis of Novel Benzazole Derivatives and Evaluation of Their Antidepressant-Like Activities with Possible Underlying Mechanisms. Molecules 2018, 23, 2881. https://doi.org/10.3390/molecules23112881

AMA Style

Tokgöz G, Demir Özkay Ü, Osmaniye D, Turan Yücel N, Can ÖD, Kaplancıklı ZA. Synthesis of Novel Benzazole Derivatives and Evaluation of Their Antidepressant-Like Activities with Possible Underlying Mechanisms. Molecules. 2018; 23(11):2881. https://doi.org/10.3390/molecules23112881

Chicago/Turabian Style

Tokgöz, Gamze, Ümide Demir Özkay, Derya Osmaniye, Nazlı Turan Yücel, Özgür Devrim Can, and Zafer Asım Kaplancıklı. 2018. "Synthesis of Novel Benzazole Derivatives and Evaluation of Their Antidepressant-Like Activities with Possible Underlying Mechanisms" Molecules 23, no. 11: 2881. https://doi.org/10.3390/molecules23112881

APA Style

Tokgöz, G., Demir Özkay, Ü., Osmaniye, D., Turan Yücel, N., Can, Ö. D., & Kaplancıklı, Z. A. (2018). Synthesis of Novel Benzazole Derivatives and Evaluation of Their Antidepressant-Like Activities with Possible Underlying Mechanisms. Molecules, 23(11), 2881. https://doi.org/10.3390/molecules23112881

Article Metrics

Back to TopTop